Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company leadership on November 10, 2015, at a price of 1366.48 pence per Ordinary Share through the GSK ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports on the following share acquisitions:
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Details: Acquisitions were made via the personal contribution and matching elements of the ShareReward Plan.
- Volume: Most participants acquired 9 shares in each element; Mr N Hirons and Ms E Walmsley acquired 10 shares in each element.
Investor Verification Checklist
- Verify the share price of 1366.48 pence against market data for November 10, 2015.
- Confirm the total number of shares acquired by each listed Director and PDMR.
- Review the terms of the GSK ShareReward Plan to understand the matching contribution structure.
- Check subsequent filings for any changes in ownership or additional transactions by these individuals.